When was Eutilex founded?

Eutilex was founded in 2015 and raised its 1st funding round 1 year after it was founded.

Where is Eutilex located?

Eutilex is headquartered in Seoul, South Korea.

Who is the current CEO of Eutilex?

Byoung S Kwon of Eutilex. They have also founded 1 company.

How many employees does Eutilex have?

As of Aug 31, 2026, the latest employee count at Eutilex is 33.

Is Eutilex a funded company?

Eutilex is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Dec 08, 2016.

When was the latest funding round of Eutilex?

Eutilex's latest funding was a $***** Series A round on Dec 08, 2016, with participation from 1 investor.

Where does Eutilex rank among its competitors?

Eutilex ranks 669th amongst 3408 active competitors, of which 1138 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Eutilex?

Eutilex's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Eutilex - 2026 Company Profile, Team, Funding & Competitors

Eutilex is a public company based in Seoul (South Korea), founded in 2015 by Byoung S Kwon. It operates as a Developing T cell-based therapeutics and antibodies for the treatment of cancer.. Eutilex has raised $18M in funding. The company has 3408 active competitors, including 1138 funded and 796 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Eutilex is developing T cell-based therapeutics and antibodies for the treatment of cancer. Its adoptive T cell therapy pipeline include EBViNT Cells (EBV/LMP2A-specific T cells) to treat Epstein-Barr Virus (EBV)-positive cancers (Phase 2b); WTiNT cell therapy (WT1-specific T cell therapeutics) for glioblastomas (Phase 1) and TERTiNT cell therapy (hTERT-specific T cell therapeutics) for various types of solid cancers (phase 1). The company is also developing CAR-T cell therapies and monoclonal antibodies for the treatment of wide range of cancers (preclinical).

Key Metrics

Founded Year

2015

Location

Seoul, South Korea

Stage

Public

Total Funding

$18M in 1 round

Latest Funding Round

Series A, Dec 08, 2016, $*****

Investors

GNTech Venture Capital & 6 more

Ranked

669^th among 3408 active competitors

Employee Count

33 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3110 more

Exit Details

Public

View Eutilex's full profile

Eutilex got listed on Dec 24, 2018.

Click here to take a look at Eutilex's IPO in detail

Eutilex has raised a total funding of $18M over 1 round. Its latest funding round was a Series A round on Dec 08, 2016 for $*****. 1 investor participated in its latest round. Eutilex has 7 institutional investors.

Here is the list of recent funding rounds of Eutilex:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 08, 2016	7689754	Series A	2903397	8605950	2612100	3352613

Access funding benchmarks and valuations. Sign up today!

View details of Eutilex's funding rounds and investors

The founders of Eutilex is Byoung S Kwon. Byoung S Kwon is the CEO of Eutilex.

Here are the details of Eutilex's key team members:

Byoung S Kwon: Founder & CEO of Eutilex.

View details of Eutilex's Founder profiles and Board Members

Eutilex's employee count trend

Eutilex has 33 employees as of Aug 26. Here is Eutilex's employee count trend over the years:

Uncover Eutilex's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Eutilex include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Eutilex, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
669th	Eutilex 2015, Seoul (South Korea), Public	Developing T cell-based therapeutics and antibodies for the treatment of cancer.	$18M	GNTech Venture Capital, DA Value Investment ... & 5 others	48/100